相关实验视频

Updated: Feb 6, 2026

Generation of Multicellular Human Primary Endometrial Organoids

Generation of Multicellular Human Primary Endometrial Organoids

Published on: October 4, 2019

在患有子宫内膜增殖性疾病的患者中,黑素对子宫内膜组织学的影响:双盲随机临床试验

Dina Salehi¹, Parvin Mostafa Gharebaghi¹, Mehri Jafari¹

¹Department of Obstetrics and Gynecology, Al-Zahra Hospital, Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Indian journal of surgical oncology

|February 5, 2026

概括

将黑激素添加到孕激素治疗中显著改善了子宫内膜激增症的治疗结果,导致异常阴道出血患者的正常化率更高.

科学领域:

妇科妇科妇科妇科
内分泌学在内分泌学.
在瘤学瘤学.

背景情况:

子宫内膜腺增生涉及子宫内膜腺和肌体的变化,从生理状态到癌症.
黑素在调节子宫内膜细胞增殖中的作用正在研究中.
新出现的证据表明,黑激素可以抑制妇科癌症.

研究的目的:

在患有子宫内膜增殖性疾病的患者中,研究美拉托尼对子宫内膜组织学的影响.
评估黑激素作为子宫内膜增生症的辅助疗法的潜力.

主要方法:

一个双盲,随机的临床试验,涉及异常阴道出血和子宫内膜增殖障碍或非非典型的增多症的患者.
患者接受了单独的Megestrol酸盐 (对照剂) 或Megestrol酸盐加上黑色素 (干预剂) 三个月.
在治疗前和治疗后进行了子宫内膜活检,以比较组织学结果.

主要成果:

与对照组相比,干预组 (94.7%) 观察到正常活检结果的比率明显高 (66.6%) (P<0.05).
该研究在最终分析中包括了40名入学患者中的37名患者.
人口信息在各组之间均质化.

结论:

将黑激素添加到孕激素治疗中可以提高子宫内膜增生症的治疗反应.
黑色素可能导致子宫内膜增殖障碍的成功治疗率更高.

关键词:

异常增殖性子宫内膜异常这是子宫内膜癌的癌症.梅格斯特醇乙酸的使用情况黑色素是什么黑色素是什么黑色素是什么非非典型的子宫内膜增生症.

更多相关视频

Establishing 3D Endometrial Organoids from the Mouse Uterus

Establishing 3D Endometrial Organoids from the Mouse Uterus

Published on: January 6, 2023

Isolation of Mouse Endometrial Epithelial and Stromal Cells for In Vitro Decidualization

Isolation of Mouse Endometrial Epithelial and Stromal Cells for In Vitro Decidualization

Published on: March 2, 2017

相关概念视频

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Blind Procedures

Blind Procedures

Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...

Statistical Software for Data Analysis and Clinical Trials

Statistical Software for Data Analysis and Clinical Trials

Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...

Blinding

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.

Proliferative Phase

Proliferative Phase

The proliferative phase typically occurs after menstruation and lasts between 6 to 13 days in a standard 28-day cycle. This phase involves the reconstruction of the endometrium, guided by estrogen produced by the developing ovarian follicle.
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...